JP2018530325A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018530325A5 JP2018530325A5 JP2018516525A JP2018516525A JP2018530325A5 JP 2018530325 A5 JP2018530325 A5 JP 2018530325A5 JP 2018516525 A JP2018516525 A JP 2018516525A JP 2018516525 A JP2018516525 A JP 2018516525A JP 2018530325 A5 JP2018530325 A5 JP 2018530325A5
- Authority
- JP
- Japan
- Prior art keywords
- modified oligonucleotide
- compound
- modified
- wing segment
- nucleoside
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 150000001875 compounds Chemical class 0.000 claims description 62
- 108091034117 Oligonucleotide Proteins 0.000 claims description 56
- 239000002777 nucleoside Substances 0.000 claims description 49
- 125000003835 nucleoside group Chemical group 0.000 claims description 29
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 16
- 150000003833 nucleoside derivatives Chemical class 0.000 claims description 12
- 230000000295 complement effect Effects 0.000 claims description 8
- 201000010099 disease Diseases 0.000 claims description 8
- 208000035475 disorder Diseases 0.000 claims description 8
- LRSASMSXMSNRBT-UHFFFAOYSA-N 5-methylcytosine Chemical group CC1=CNC(=O)N=C1N LRSASMSXMSNRBT-UHFFFAOYSA-N 0.000 claims description 6
- 241001465754 Metazoa Species 0.000 claims description 4
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical group NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 claims description 4
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 claims description 4
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical group CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 claims description 4
- 206010020772 Hypertension Diseases 0.000 claims description 3
- OVRNDRQMDRJTHS-KEWYIRBNSA-N N-acetyl-D-galactosamine Chemical compound CC(=O)N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-KEWYIRBNSA-N 0.000 claims description 3
- 229930024421 Adenine Natural products 0.000 claims description 2
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 claims description 2
- MBLBDJOUHNCFQT-UHFFFAOYSA-N N-acetyl-D-galactosamine Natural products CC(=O)NC(C=O)C(O)C(O)C(O)CO MBLBDJOUHNCFQT-UHFFFAOYSA-N 0.000 claims description 2
- 229960000643 adenine Drugs 0.000 claims description 2
- 125000002619 bicyclic group Chemical group 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 2
- 210000000056 organ Anatomy 0.000 claims description 2
- 230000037361 pathway Effects 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- 238000002560 therapeutic procedure Methods 0.000 claims description 2
- 229940113082 thymine Drugs 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 10
- 208000019622 heart disease Diseases 0.000 claims 2
- 206010019280 Heart failures Diseases 0.000 claims 1
- 208000001826 Marfan syndrome Diseases 0.000 claims 1
- 150000001450 anions Chemical class 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 208000018578 heart valve disease Diseases 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 230000007170 pathology Effects 0.000 claims 1
- 208000015658 resistant hypertension Diseases 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 6
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021160831A JP2022008677A (ja) | 2015-10-08 | 2021-09-30 | アンジオテンシノーゲンの発現を調節するための化合物及び方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562238831P | 2015-10-08 | 2015-10-08 | |
| US62/238,831 | 2015-10-08 | ||
| PCT/US2016/056068 WO2017062816A2 (en) | 2015-10-08 | 2016-10-07 | Compounds and methods for modulating angiotensinogen expression |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021160831A Division JP2022008677A (ja) | 2015-10-08 | 2021-09-30 | アンジオテンシノーゲンの発現を調節するための化合物及び方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018530325A JP2018530325A (ja) | 2018-10-18 |
| JP2018530325A5 true JP2018530325A5 (OSRAM) | 2020-11-05 |
Family
ID=58488579
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018516525A Ceased JP2018530325A (ja) | 2015-10-08 | 2016-10-07 | アンジオテンシノーゲンの発現を調節するための化合物及び方法 |
| JP2021160831A Ceased JP2022008677A (ja) | 2015-10-08 | 2021-09-30 | アンジオテンシノーゲンの発現を調節するための化合物及び方法 |
| JP2023069869A Pending JP2023093644A (ja) | 2015-10-08 | 2023-04-21 | アンジオテンシノーゲンの発現を調節するための化合物及び方法 |
| JP2024168190A Pending JP2025011138A (ja) | 2015-10-08 | 2024-09-27 | アンジオテンシノーゲンの発現を調節するための化合物及び方法 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021160831A Ceased JP2022008677A (ja) | 2015-10-08 | 2021-09-30 | アンジオテンシノーゲンの発現を調節するための化合物及び方法 |
| JP2023069869A Pending JP2023093644A (ja) | 2015-10-08 | 2023-04-21 | アンジオテンシノーゲンの発現を調節するための化合物及び方法 |
| JP2024168190A Pending JP2025011138A (ja) | 2015-10-08 | 2024-09-27 | アンジオテンシノーゲンの発現を調節するための化合物及び方法 |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US10912792B2 (OSRAM) |
| EP (3) | EP4474389A3 (OSRAM) |
| JP (4) | JP2018530325A (OSRAM) |
| KR (2) | KR20240033305A (OSRAM) |
| CN (2) | CN108271351B (OSRAM) |
| AU (3) | AU2016334114B2 (OSRAM) |
| BR (2) | BR122020023854B1 (OSRAM) |
| CA (1) | CA2998898A1 (OSRAM) |
| CL (2) | CL2018000899A1 (OSRAM) |
| CO (1) | CO2018002598A2 (OSRAM) |
| HK (1) | HK1258275A1 (OSRAM) |
| IL (2) | IL295971A (OSRAM) |
| MX (2) | MX392014B (OSRAM) |
| MY (1) | MY200263A (OSRAM) |
| PE (1) | PE20181085A1 (OSRAM) |
| SG (1) | SG10202003148VA (OSRAM) |
| WO (1) | WO2017062816A2 (OSRAM) |
| ZA (1) | ZA201801600B (OSRAM) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA201692370A1 (ru) | 2014-05-22 | 2017-03-31 | Элнилэм Фармасьютикалз, Инк. | КОМПОЗИЦИИ иРНК АНГИОТЕНЗИНОГЕНА (AGT) И СПОСОБЫ ИХ ИСПОЛЬЗОВАНИЯ |
| TWI851574B (zh) * | 2018-05-14 | 2024-08-11 | 美商阿尼拉製藥公司 | 血管收縮素原（ＡＧＴ）ｉＲＮＡ組成物及其使用方法 |
| US20220243210A1 (en) * | 2019-05-17 | 2022-08-04 | Ionis Pharmaceuticals, Inc. | Angiotensin ii type 1 receptor targeted oligonucleotides and uses thereof |
| KR20220115946A (ko) * | 2019-11-13 | 2022-08-19 | 알닐람 파마슈티칼스 인코포레이티드 | 안지오텐시노겐 (agt) 관련 장애를 치료하기 위한 방법 및 조성물 |
| US11649458B2 (en) * | 2020-05-05 | 2023-05-16 | University Of Kentucky Research Foundation | Inhibiting angiotensinogen to attenuate aortic pathology in Marfan syndrome |
| LT4136092T (lt) | 2020-11-18 | 2024-09-25 | Ionis Pharmaceuticals, Inc. | Junginiai ir būdai, skirti angiotenzinogeno raiškos moduliavimui |
| CN114763547A (zh) * | 2021-01-14 | 2022-07-19 | 施能康生物科技有限公司 | 靶向血管紧张素原的核酸及其用途 |
| WO2022232650A1 (en) * | 2021-04-30 | 2022-11-03 | Ionis Pharmaceuticals, Inc. | Methods for reducing agt expression |
| JP2024536146A (ja) * | 2021-10-01 | 2024-10-04 | エーダーエックス ファーマシューティカルズ， インコーポレイテッド | アンジオテンシノーゲンを調節する組成物及びその使用方法 |
| CN120775847A (zh) * | 2021-10-20 | 2025-10-14 | 厦门甘宝利生物医药有限公司 | Agt抑制剂及其用途 |
| EP4435103A4 (en) * | 2021-11-16 | 2025-11-26 | Shanghai Argo Biopharmaceutical Co Ltd | COMPOSITION AND METHOD OF INHIBITING THE EXPRESSION OF ANGIOTENSINOGEN PROTEIN (AGT) |
| US20250197853A1 (en) * | 2021-11-19 | 2025-06-19 | Tuojie Biotech (Shanghai) Co., Ltd. | Sirna targeting angiotensinogen and pharmaceutical use of sirna |
| TW202339773A (zh) * | 2022-01-20 | 2023-10-16 | 大陸商上海拓界生物醫藥科技有限公司 | 一種ｄｓＲＮＡ、其應用及製備方法 |
| CN117264948B (zh) * | 2022-06-14 | 2024-05-10 | 广州必贝特医药股份有限公司 | 抑制血管紧张素原基因表达的RNAi抑制剂及其应用 |
| WO2024013334A1 (en) * | 2022-07-15 | 2024-01-18 | Silence Therapeutics Gmbh | Nucleic acids for inhibiting expression of agt in a cell |
| US20240108741A1 (en) * | 2022-08-03 | 2024-04-04 | Sirnaomics, Inc. | COMBINATION siRNA AND PEPTIDE DOCKING VEHICLE (PDoV) COMPOSITIONS AND METHODS OF THEIR USE FOR IMPROVED REGULATION AND FUNCTIONALITY |
| WO2024059881A2 (en) * | 2022-09-16 | 2024-03-21 | Sirnaomics, Inc. | Products and compositions |
| WO2024137700A2 (en) * | 2022-12-20 | 2024-06-27 | Sirius Therapeutics, Inc. | Polynucleic acid molecules targeting agt and uses thereof |
| WO2024138136A1 (en) * | 2022-12-22 | 2024-06-27 | Sirnaomics, Inc. | Products and compositions |
| CN119530218A (zh) * | 2023-08-30 | 2025-02-28 | 苏州炫景生物科技有限公司 | 双链寡核苷酸及其在抑制血管紧张素原表达中的应用 |
| WO2024234831A1 (zh) * | 2023-05-15 | 2024-11-21 | 苏州时安生物技术有限公司 | 一种用于调节血管紧张素原基因表达的双链rna、其缀合物、药物组合物及用途 |
| WO2024259134A1 (en) | 2023-06-13 | 2024-12-19 | Arnatar Therapeutics, Inc | Advanced rna targeting (arnatar) for angiotensinogen |
| WO2025097040A1 (en) * | 2023-11-03 | 2025-05-08 | Ionis Pharmaceuticals, Inc. | Methods and compositions for reducing angiotensinogen |
| CN118995714B (zh) * | 2024-09-26 | 2025-12-12 | 杭州天龙药业有限公司 | 靶向抑制AGT基因表达的siRNA及其在治疗高血压中的应用 |
Family Cites Families (81)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5118800A (en) | 1983-12-20 | 1992-06-02 | California Institute Of Technology | Oligonucleotides possessing a primary amino group in the terminal nucleotide |
| FR2567892B1 (fr) | 1984-07-19 | 1989-02-17 | Centre Nat Rech Scient | Nouveaux oligonucleotides, leur procede de preparation et leurs applications comme mediateurs dans le developpement des effets des interferons |
| US5166315A (en) | 1989-12-20 | 1992-11-24 | Anti-Gene Development Group | Sequence-specific binding polymers for duplex nucleic acids |
| US5034506A (en) | 1985-03-15 | 1991-07-23 | Anti-Gene Development Group | Uncharged morpholino-based polymers having achiral intersubunit linkages |
| US5185444A (en) | 1985-03-15 | 1993-02-09 | Anti-Gene Deveopment Group | Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages |
| US5506337A (en) | 1985-03-15 | 1996-04-09 | Antivirals Inc. | Morpholino-subunit combinatorial library and method |
| US5591722A (en) | 1989-09-15 | 1997-01-07 | Southern Research Institute | 2'-deoxy-4'-thioribonucleosides and their antiviral activity |
| AU658562B2 (en) | 1989-10-24 | 1995-04-27 | Isis Pharmaceuticals, Inc. | 2' modified oligonucleotides |
| US5646265A (en) | 1990-01-11 | 1997-07-08 | Isis Pharmceuticals, Inc. | Process for the preparation of 2'-O-alkyl purine phosphoramidites |
| US5670633A (en) | 1990-01-11 | 1997-09-23 | Isis Pharmaceuticals, Inc. | Sugar modified oligonucleotides that detect and modulate gene expression |
| GB9009980D0 (en) | 1990-05-03 | 1990-06-27 | Amersham Int Plc | Phosphoramidite derivatives,their preparation and the use thereof in the incorporation of reporter groups on synthetic oligonucleotides |
| ES2116977T3 (es) | 1990-05-11 | 1998-08-01 | Microprobe Corp | Soportes solidos para ensayos de hibridacion de acidos nucleicos y metodos para inmovilizar oligonucleotidos de modo covalente. |
| US6582908B2 (en) | 1990-12-06 | 2003-06-24 | Affymetrix, Inc. | Oligonucleotides |
| EP0538194B1 (de) | 1991-10-17 | 1997-06-04 | Novartis AG | Bicyclische Nukleoside, Oligonukleotide, Verfahren zu deren Herstellung und Zwischenprodukte |
| US5359044A (en) | 1991-12-13 | 1994-10-25 | Isis Pharmaceuticals | Cyclobutyl oligonucleotide surrogates |
| FR2687679B1 (fr) | 1992-02-05 | 1994-10-28 | Centre Nat Rech Scient | Oligothionucleotides. |
| EP0577558A2 (de) | 1992-07-01 | 1994-01-05 | Ciba-Geigy Ag | Carbocyclische Nukleoside mit bicyclischen Ringen, Oligonukleotide daraus, Verfahren zu deren Herstellung, deren Verwendung und Zwischenproduckte |
| DK0691968T3 (da) | 1993-03-30 | 1998-02-23 | Sanofi Sa | Acykliske nukleosid-analoge og oligonukleotidsekvenser indeholdende disse |
| US5801154A (en) | 1993-10-18 | 1998-09-01 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of multidrug resistance-associated protein |
| US5446137B1 (en) | 1993-12-09 | 1998-10-06 | Behringwerke Ag | Oligonucleotides containing 4'-substituted nucleotides |
| US5519134A (en) | 1994-01-11 | 1996-05-21 | Isis Pharmaceuticals, Inc. | Pyrrolidine-containing monomers and oligomers |
| US5627053A (en) | 1994-03-29 | 1997-05-06 | Ribozyme Pharmaceuticals, Inc. | 2'deoxy-2'-alkylnucleotide containing nucleic acid |
| US5597909A (en) | 1994-08-25 | 1997-01-28 | Chiron Corporation | Polynucleotide reagents containing modified deoxyribose moieties, and associated methods of synthesis and use |
| AU1039397A (en) | 1995-11-22 | 1997-06-27 | Johns Hopkins University, The | Ligands to enhance cellular uptake of biomolecules |
| CA2248932A1 (en) | 1996-03-15 | 1997-09-18 | University Of Florida | Oligonucleotides targeted to angiotensinogen mrna |
| US7875733B2 (en) | 2003-09-18 | 2011-01-25 | Isis Pharmaceuticals, Inc. | Oligomeric compounds comprising 4′-thionucleosides for use in gene modulation |
| JP3756313B2 (ja) | 1997-03-07 | 2006-03-15 | 武 今西 | 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体 |
| US6770748B2 (en) | 1997-03-07 | 2004-08-03 | Takeshi Imanishi | Bicyclonucleoside and oligonucleotide analogue |
| DE69829760T3 (de) | 1997-09-12 | 2016-04-14 | Exiqon A/S | Bi- und tri-zyklische - nukleosid, nukleotid und oligonukleotid-analoga |
| US6794499B2 (en) | 1997-09-12 | 2004-09-21 | Exiqon A/S | Oligonucleotide analogues |
| US20030228597A1 (en) | 1998-04-13 | 2003-12-11 | Cowsert Lex M. | Identification of genetic targets for modulation by oligonucleotides and generation of oligonucleotides for gene modulation |
| US6300319B1 (en) | 1998-06-16 | 2001-10-09 | Isis Pharmaceuticals, Inc. | Targeted oligonucleotide conjugates |
| US6043352A (en) | 1998-08-07 | 2000-03-28 | Isis Pharmaceuticals, Inc. | 2'-O-Dimethylaminoethyloxyethyl-modified oligonucleotides |
| TR200102581T2 (tr) | 1999-03-05 | 2002-04-22 | G.D. Searle Llc | Kardiovasküler hastalığın tedavisi için anjiyotensin konversiyon enzimi inhibitörünün ve epoksi-sterodial aldosteron antagonistinin kombinasyon terapisi. |
| BR0009884A (pt) | 1999-04-21 | 2002-01-08 | American Home Prod | Processos e composições para a inibição da função das sequências de polinucleotìdeos |
| JP2002543214A (ja) | 1999-05-04 | 2002-12-17 | エクシコン エ／エス | Ｌ−リボ−ｌｎａ類縁体 |
| US6525191B1 (en) | 1999-05-11 | 2003-02-25 | Kanda S. Ramasamy | Conformationally constrained L-nucleosides |
| AU5016200A (en) | 1999-05-21 | 2000-12-12 | Myriad Genetics, Inc. | Diabetes gene |
| US6902888B1 (en) | 1999-05-21 | 2005-06-07 | Myriad Genetics, Inc. | Diabetes gene |
| WO2001049687A2 (en) | 1999-12-30 | 2001-07-12 | K. U. Leuven Research & Development | Cyclohexene nucleic acids |
| US7491805B2 (en) | 2001-05-18 | 2009-02-17 | Sirna Therapeutics, Inc. | Conjugates and compositions for cellular delivery |
| EP1355672A2 (en) | 2000-12-01 | 2003-10-29 | Cell Works Inc. | Conjugates of glycosylated/galactosylated peptide, bifunctional linker, and nucleotidic monomers/polymers, and related compositions and methods of use |
| WO2003004602A2 (en) | 2001-07-03 | 2003-01-16 | Isis Pharmaceuticals, Inc. | Nuclease resistant chimeric oligonucleotides |
| WO2004044139A2 (en) | 2002-11-05 | 2004-05-27 | Isis Parmaceuticals, Inc. | Modified oligonucleotides for use in rna interference |
| WO2004041889A2 (en) | 2002-11-05 | 2004-05-21 | Isis Pharmaceuticals, Inc. | Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation |
| DK2284266T3 (da) | 2002-11-14 | 2014-01-13 | Thermo Fisher Scient Biosciences Inc | sIRNA-MOLEKYLE MOD TP53 |
| US6673661B1 (en) | 2002-12-20 | 2004-01-06 | Taiwan Semiconductor Manufacturing Co., Ltd. | Self-aligned method for forming dual gate thin film transistor (TFT) device |
| US20040185559A1 (en) | 2003-03-21 | 2004-09-23 | Isis Pharmaceuticals Inc. | Modulation of diacylglycerol acyltransferase 1 expression |
| US7723509B2 (en) | 2003-04-17 | 2010-05-25 | Alnylam Pharmaceuticals | IRNA agents with biocleavable tethers |
| WO2004106356A1 (en) | 2003-05-27 | 2004-12-09 | Syddansk Universitet | Functionalized nucleotide derivatives |
| DK1661905T3 (da) | 2003-08-28 | 2012-07-23 | Takeshi Imanishi | Hidtil ukendte syntetiske nukleinsyrer af N-O-krydsbindingstype |
| WO2005121372A2 (en) | 2004-06-03 | 2005-12-22 | Isis Pharmaceuticals, Inc. | Double strand compositions comprising differentially modified strands for use in gene modulation |
| EP1799859B1 (en) | 2004-09-17 | 2014-07-02 | Isis Pharmaceuticals, Inc. | Enhanced antisense oligonucleotides |
| WO2006047842A2 (en) | 2004-11-08 | 2006-05-11 | K.U. Leuven Research And Development | Modified nucleosides for rna interference |
| US20060148740A1 (en) | 2005-01-05 | 2006-07-06 | Prosensa B.V. | Mannose-6-phosphate receptor mediated gene transfer into muscle cells |
| US7399845B2 (en) | 2006-01-27 | 2008-07-15 | Isis Pharmaceuticals, Inc. | 6-modified bicyclic nucleic acid analogs |
| CN101490074B (zh) | 2006-05-11 | 2013-06-26 | Isis制药公司 | 5’-修饰的双环核酸类似物 |
| US20100190837A1 (en) | 2007-02-15 | 2010-07-29 | Isis Pharmaceuticals, Inc. | 5'-Substituted-2-F' Modified Nucleosides and Oligomeric Compounds Prepared Therefrom |
| DK2170917T3 (da) | 2007-05-30 | 2012-10-08 | Isis Pharmaceuticals Inc | N-Substituerede bicycliske nukleinsyreanaloge med aminomethylenbro |
| ES2386492T3 (es) | 2007-06-08 | 2012-08-21 | Isis Pharmaceuticals, Inc. | Análogos de ácidos nucleicos bicíclicos carbocíclicos |
| ATE538127T1 (de) | 2007-07-05 | 2012-01-15 | Isis Pharmaceuticals Inc | 6-disubstituierte bicyclische nukleinsäureanaloga |
| WO2009067647A1 (en) | 2007-11-21 | 2009-05-28 | Isis Pharmaceuticals, Inc. | Carbocyclic alpha-l-bicyclic nucleic acid analogs |
| CA2930393C (en) | 2007-12-04 | 2022-11-29 | Alnylam Pharmaceuticals, Inc. | Carbohydrate conjugates as delivery agents for oligonucleotides |
| US8530640B2 (en) | 2008-02-07 | 2013-09-10 | Isis Pharmaceuticals, Inc. | Bicyclic cyclohexitol nucleic acid analogs |
| EP3604533A1 (en) | 2008-04-11 | 2020-02-05 | Arbutus Biopharma Corporation | Site-specific delivery of nucleic acids by combining targeting ligands with endosomolytic components |
| CN103429270B (zh) | 2008-08-25 | 2016-11-23 | 埃克斯雷德制药有限公司 | 阻止结缔组织生长因子的反义核苷酸及其用途 |
| DK2361256T3 (da) | 2008-09-24 | 2013-07-01 | Isis Pharmaceuticals Inc | Cyclohexenyl-nukleinsyreanaloger |
| DK2356129T3 (da) | 2008-09-24 | 2013-05-13 | Isis Pharmaceuticals Inc | Substituerede alpha-L-bicykliske nukleosider |
| US9012421B2 (en) | 2009-08-06 | 2015-04-21 | Isis Pharmaceuticals, Inc. | Bicyclic cyclohexose nucleic acid analogs |
| JP2013506684A (ja) | 2009-10-01 | 2013-02-28 | シンフォニー エボリューション， インコーポレイテッド | マトリックスメタロプロテアーゼ−２阻害剤を用いた、動脈瘤性拡張、血管壁脆弱性、特に腹部大動脈瘤および胸部動脈瘤を治療する方法 |
| JP6005628B2 (ja) | 2010-04-28 | 2016-10-12 | アイオーニス ファーマシューティカルズ， インコーポレーテッドＩｏｎｉｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． | 修飾ヌクレオシド、その類似体、およびこれらから調製されるオリゴマー化合物 |
| EP2593099A1 (en) | 2010-07-12 | 2013-05-22 | DKFZ Deutsches Krebsforschungszentrum | Wogonin for the prevention and therapy of cardiac hypertrophy |
| WO2012037254A1 (en) | 2010-09-15 | 2012-03-22 | Alnylam Pharmaceuticals, Inc. | MODIFIED iRNA AGENTS |
| CN102260673A (zh) * | 2011-07-12 | 2011-11-30 | 深圳职业技术学院 | 靶向人血管紧张素原的rna干扰片段、表达载体与应用 |
| US10023861B2 (en) | 2011-08-29 | 2018-07-17 | Ionis Pharmaceuticals, Inc. | Oligomer-conjugate complexes and their use |
| US20150297629A1 (en) | 2012-07-27 | 2015-10-22 | Isis Pharmaceuticals, Inc. | Modulation of renin-angiotensin system (ras) related diseases by angiotensinogen |
| CN103103192A (zh) * | 2013-01-18 | 2013-05-15 | 深圳职业技术学院 | 靶向血管紧张素原的rna干扰片段、其表达载体、混合克隆细胞株及其应用 |
| NZ630921A (en) | 2013-05-01 | 2017-12-22 | Regulus Therapeutics Inc | Compounds and methods for enhanced cellular uptake |
| US9127276B2 (en) | 2013-05-01 | 2015-09-08 | Isis Pharmaceuticals, Inc. | Conjugated antisense compounds and their use |
| EA201692370A1 (ru) * | 2014-05-22 | 2017-03-31 | Элнилэм Фармасьютикалз, Инк. | КОМПОЗИЦИИ иРНК АНГИОТЕНЗИНОГЕНА (AGT) И СПОСОБЫ ИХ ИСПОЛЬЗОВАНИЯ |
| US10709728B2 (en) * | 2015-06-01 | 2020-07-14 | Alnylam Pharmaceuticals, Inc. | Polynucleotide agents targeting angiotensinogen (AGT) and methods of use thereof |
-
2016
- 2016-10-07 JP JP2018516525A patent/JP2018530325A/ja not_active Ceased
- 2016-10-07 KR KR1020247007192A patent/KR20240033305A/ko active Pending
- 2016-10-07 SG SG10202003148VA patent/SG10202003148VA/en unknown
- 2016-10-07 WO PCT/US2016/056068 patent/WO2017062816A2/en not_active Ceased
- 2016-10-07 HK HK19100639.6A patent/HK1258275A1/zh unknown
- 2016-10-07 IL IL295971A patent/IL295971A/en unknown
- 2016-10-07 AU AU2016334114A patent/AU2016334114B2/en active Active
- 2016-10-07 CN CN201680058511.6A patent/CN108271351B/zh active Active
- 2016-10-07 PE PE2018000423A patent/PE20181085A1/es unknown
- 2016-10-07 EP EP24190082.8A patent/EP4474389A3/en active Pending
- 2016-10-07 KR KR1020187012472A patent/KR20180055898A/ko not_active Abandoned
- 2016-10-07 CA CA2998898A patent/CA2998898A1/en active Pending
- 2016-10-07 BR BR122020023854-2A patent/BR122020023854B1/pt active IP Right Grant
- 2016-10-07 MX MX2018004307A patent/MX392014B/es unknown
- 2016-10-07 BR BR112018005223-0A patent/BR112018005223B1/pt not_active IP Right Cessation
- 2016-10-07 MY MYPI2018701353A patent/MY200263A/en unknown
- 2016-10-07 US US15/763,942 patent/US10912792B2/en active Active
- 2016-10-07 EP EP21185493.0A patent/EP3960183A1/en not_active Withdrawn
- 2016-10-07 EP EP16854454.2A patent/EP3359164A4/en not_active Withdrawn
- 2016-10-07 CN CN202111106191.6A patent/CN113817735A/zh active Pending
-
2018
- 2018-03-08 IL IL257989A patent/IL257989B2/en unknown
- 2018-03-08 ZA ZA2018/01600A patent/ZA201801600B/en unknown
- 2018-03-13 CO CONC2018/0002598A patent/CO2018002598A2/es unknown
- 2018-04-06 CL CL2018000899A patent/CL2018000899A1/es unknown
- 2018-04-06 MX MX2022005200A patent/MX2022005200A/es unknown
-
2020
- 2020-05-29 CL CL2020001453A patent/CL2020001453A1/es unknown
- 2020-11-23 US US17/101,299 patent/US20220000901A1/en active Pending
-
2021
- 2021-09-30 JP JP2021160831A patent/JP2022008677A/ja not_active Ceased
-
2022
- 2022-04-22 AU AU2022202671A patent/AU2022202671A1/en not_active Abandoned
-
2023
- 2023-04-21 JP JP2023069869A patent/JP2023093644A/ja active Pending
-
2024
- 2024-05-23 AU AU2024203439A patent/AU2024203439A1/en active Pending
- 2024-09-27 JP JP2024168190A patent/JP2025011138A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018530325A5 (OSRAM) | ||
| JP2018199700A5 (OSRAM) | ||
| RU2017137410A (ru) | Соединения и способы модулирования экспрессии tmprss6 | |
| JP2018511307A5 (OSRAM) | ||
| JP2020511155A5 (OSRAM) | ||
| JP2021074021A5 (OSRAM) | ||
| JP2021072840A5 (OSRAM) | ||
| JP2022106727A5 (OSRAM) | ||
| CN102123716B (zh) | 用于治疗病毒感染的化合物和方法 | |
| JP2020193199A5 (OSRAM) | ||
| JP2014530004A5 (OSRAM) | ||
| JP2010539950A5 (OSRAM) | ||
| JP2020111594A5 (OSRAM) | ||
| JP2018126141A5 (OSRAM) | ||
| RU2014119787A (ru) | Антисмысловая регуляция экспрессии gccr | |
| RU2015151200A (ru) | Композиции и способы модулирования экспрессии аполипопротеина (а) | |
| JP2016533751A5 (OSRAM) | ||
| JP2016523548A5 (OSRAM) | ||
| JP2012050438A5 (OSRAM) | ||
| JP2018530560A5 (OSRAM) | ||
| RU2014115215A (ru) | Антисмысловая регуляция экспрессии gcgr | |
| US20030147813A1 (en) | Method for treating chronic myelogenous leukemia | |
| WO2015011694A2 (en) | Isotopologues of smad7 antisense oligonucleotides | |
| JP2016513110A5 (OSRAM) | ||
| RU2016146819A (ru) | Композиции и способы модулирования экспрессии рецептора гормона роста |